Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for SGEN
38.84
+0.27 (0.70%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.00 - 40.24
52 week 28.15 - 55.99
Open 38.42
Vol / Avg. 1.32M/1.26M
Mkt cap 4.78B
P/E     -
Div/yield     -
EPS -0.51
Shares 123.11M
Beta 1.17
Inst. own 104%
May 16, 2014
Seattle Genetics Annual Shareholder Meeting - 2:00PM EDT - Add to calendar
May 1, 2014
Q1 2014 Seattle Genetics Earnings Conference Call - 4:30PM EDT - Add to calendar
May 1, 2014
Q1 2014 Seattle Genetics Earnings Release - 4:00PM EDT - Add to calendar
Apr 8, 2014
Seattle Genetics at Needham Healthcare Conference
Mar 4, 2014
Seattle Genetics at Cowen Health Care Conference - Webcast
Feb 13, 2014
Seattle Genetics at Leerink Swann Global Healthcare Conference - Webcast
Feb 11, 2014
Q4 2013 Seattle Genetics Earnings Conference Call - Webcast
Feb 11, 2014
Q4 2013 Seattle Genetics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -23.25% -23.22%
Operating margin -23.26% -23.35%
EBITD margin - -20.15%
Return on average assets -13.07% -13.09%
Return on average equity -27.06% -27.40%
Employees 582 -
CDP Score - -

Address

21823 30TH DRIVE SE
BOTHELL, WA 98021
United States - Map
+1-425-5274000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 44
Bio & Compensation  - Reuters
Christopher S. Boerner Ph.D. Executive Vice President - Commercial
Age: 43
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Bio & Compensation  - Reuters
Vaughn B. Himes Ph.D. Executive Vice President - Technical Operations, Process Sciences
Age: 52
Bio & Compensation  - Reuters
Kirk Schumacher Senior Vice President - Legal Affairs and Compliance, General Counsel
Bio & Compensation  - Reuters
Charles R. Romp Senior Vice President - Sales
Bio & Compensation  - Reuters
Eric Sievers M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 44
Bio & Compensation  - Reuters